Digital health technology company NeuroRPM received FDA 510(k) clearance for its AI-enabled remote monitoring app that uses a apple watch to track common symptoms of Parkinson’s disease such as bradykinesia, tremors and dyskinesia.
Bradykinesia is slowness of movement and dyskinesia is involuntary or erratic movement.
The Washington, DC-based company’s algorithms are embedded in the Apple Watch app and continuously analyze wearable device user data to monitor these symptoms and health parameters related to Parkinson’s disease.
“We’re excited to be on the new frontier of digital health with NeuroRPM. By leveraging the power of Apple Watch, we’re transforming the way people with Parkinson’s understand their health, empowering providers to care to make more informed clinical decisions that will lead to better health outcomes. We are honored to contribute to this healthcare revolution,” said Atila Omer, President of NeuroRPM.
THE GREAT TREND
Another digital health company using the Apple Watch to monitor Parkinson’s patients is a brain data startup Rune Laboratories.
Last year, Rune scored FDA 510(k) clearance for its StrivePD app, which uses Apple’s Movement Disorder API to track tremors and dyskinesia. Patients can also use StrivePD to log their medications, side effects, and other symptoms.
Earlier this month, Rune announced a partnership with BlueRock Therapeutics, a clinical-stage biopharmaceutical company and a subsidiary of Bayer AG, to help study Parkinson’s disease using its StrivePD platform.
Other companies looking to help people with neurodegenerative movement disorders include a Maine-based digital prescription therapy startup MedRhythmswhich seeks to improve the mobility of people with multiple sclerosis, and based in London SERG Technologieswhich offers wearable sensor technologies to monitor the severity of symptoms of Parkinson’s disease.
Tracy Chu will offer more details during her HIMSS23 session “Automation Improves Performance in Digital Education Applications”. It is scheduled for Wednesday, April 19 from 11:30 a.m. to 12:30 p.m. CT at the South Building, Level 5, Room S505.